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Abstract Streptococcus infections are still one of the impor-
tant problems facing contemporary medicine. As the World
Health Organization (WHO)warns, Streptococcus pneumoniae
is responsible for the highest number of pneumonia cases all
over the world. Despite an increasing number of pneumococcal
vaccinations, incidences of disease connected to this pathogen’s
infection stay at the same level, which is related to a constantly
increasing number of infections caused by nonvaccinal sero-
types. Unfortunately, the pathogenicity of bacteria of the Strep-
tococcus genus is also connected to species considered to be
physiological flora in humans or animals and, additionally, new
species exhibiting pathogenic potential have been discovered.
This paper presents an opinion concerning the epidemiology of
streptococci infections based on case studies and other publi-
cations devoted to this problem. It also sheds new light based
on recent reports on the prevention of protective vaccinations
application in the case of streptococci infections.
Selected factors of the pathogenicity of streptococci
described in this paper
The term pathogenicity determinant refers to those features
which determine the ability of a microorganism to cause a
disease, but which are not themselves required for its surviv-
al [1]. Henderson et al. define pathogenicity determinants as
pathogen components which cause damage in a host organ-
ism; this may include factors which are important for
pathogen survival [2]. These definitions, however, do not
take into account the role of host susceptibility to infection;
instead, they note only those features of the pathogen which
are responsible for disease development. According to these
definitions, only those organisms which cause diseases in
healthy people are pathogens, while opportunistic or com-
mensal microorganisms, which are only able to infect hosts
with immune system disorders, are not considered to be
pathogens.
Casadevall and Pirofski [3] proposed a new definition of
pathogenicity and pathogenicity determinants for microor-
ganisms which encompassed the state of a host’s immuno-
logical defenses. The pathogenicity of a given microorgan-
ism was expressed as the degree of damage caused both by
the microorganism itself and by the immune system in re-
sponse to the pathogen.
One of the most invasive groups of bacteria is the Strep-
tococcus genus. It is divided into 49 species and eight sub-
species, from which as many as 35 have been identified as
sources of invasive infections in humans. Microorganisms
considered to be the cause of common infections include: S.
pneumoniae, S. pyogenes—group A (group A Streptococ-
cus, GAS), S. agalactiae—group B (group B Streptococcus,
GBS), and S. mutans [4].
According to the estimations of the World Health Orga-
nization (WHO), about 1.2 million children aged below 5-
years die each year as a result of pneumonia, for which the
main casual factor is S. pneumoniae, and this constitutes
18 % of all deaths in this age group [5]. The high incidence
of the above diseases and the mortality related to S.
pneumoniae infections have prompted scientists to seek to
develop vaccines aimed at reducing the incidence of such
infections. It is known that the main factor underlying mi-
croorganism pathogenicity is the so-called polysaccharide
envelope [6], which was the basis of the division of the S.
pneumoniae microorganism into over 90 serotypes [7–9].
Seventeen immunogenic proteins have been identified on
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this microorganism surface, and the occurrence of 13 of them
is dependent on the host age [4]. Polysaccharide antigens are
used in anti-pneumococcal vaccines. They are conjugated in
the vaccines with proteins in order to enhance the immuno-
logical response, i.e., with respect to that which would occur
during natural infection by bacteria within the polysaccha-
ride envelope [10]. Conjugation of these substances allows
successful immunization of children before the second
year of life, who are, at this age, a reservoir of numerous
opportunistic pathogenic bacteria [8].
S. pneumoniae is characterized by significant genetic flex-
ibility and, thus, is subject to natural transformations which
allow it to obtain new phenotypic features. Recombinations
occurring in this manner within the polysaccharide envelope
enable the microorganism to circumvent the barrier formed by
the host’s immune system [4]. Therefore, numerous types of
vaccines against S. pneumoniae have been created so far, and
further research on bacterial strains has formed the basis for
widening the list of antigens which may constitute a potential
target for the activity of future generations of vaccines.
The next most common cause of diseases and mortality
worldwide are invasive GAS infections. S. pyogenes are re-
sponsible for about 700 million infections per year, which
result in the death of about 500,000 people [11]. One of the
most common S. pyogenes strains is the strainM1T1, which is
responsible for both pharyngitis and more severe conditions,
such as necrotizing fasciitis or toxic shock syndrome. This
bacteria is equipped with flagella referred to as antigen T.
However, unlike the flagella observed in S. pneumoniae, the
presence of the flagella in S. pyogenes causes decreased
invasiveness and pathogenicity of the strain. Despite the sim-
ilarity of both kinds of flagella in general, i.e., the main genetic
structure, fine differences in particular genes enable functional
diversity between the encoded proteins. The flagella of the
M1T1 strain increase the adhesive abilities of the proteins
towards the endothelium; however, they concurrently consti-
tute a molecular pattern for phagocytary cells of the host, and,
thus, are subject to higher activity and faster elimination from
an organism [12].
During a study conducted on S. pyogenes, 66 new proteins
related to the cell membrane were identified for the first time
on the surface of this microorganism, and as many as half of
them are immunoreactive proteins and 23 are exposed on the
cell surface [4]. Such huge differentiation of surface proteins
enables wide-ranging research to be conducted on vaccines,
the target of whose activity would be various kinds of anti-
gens. One of the main factors of S. pyogenes pathogenicity is
streptococcal pyrogenic exotoxin B (SpeB) of an activity of
cysteine protease [4]. SpeB is formed by most GAS strains,
and, therefore, any decrease in virulence may also be affected
by an inhibition of speB gene expression or by the chemical
inactivation of the protein itself. Other factors affecting GAS
virulence also include: streptolysin O, protein M, SpeA, or
streptokinase, which are also targets of therapeutic activity
during infections. Despite extensive studies on GAS, no li-
censed vaccine against this group of microorganisms has been
created so far [11]. This is influenced, inter alia, by the large
serotypic differentiation of protein M, which was considered
at the beginning of the 21st century to offer the potential for
vaccine applications [4, 11]. A 6-valent vaccine against GAS
containing N-end parts of six serotypes of protein M and
tested on animals gave a desirable effect—an increase in the
level of antibodies directed towards antigens contained within
it. In the first stage of clinical trials, an increase in the number
of antibodies was also demonstrated, and, additionally, no
cross-reactions with human tissues were reported. The vaccine
is the subject of further tests; however, a disadvantage attrib-
uted to it is its defense against only 6 of the 120 suggested
serotypes of protein M [4]. The development of genetic re-
search conducted on S. pyogenes may, in the future, allow an
elaboration of methods which would identify antigens suitable
for application in vaccines. Such research was performed in
silico by Sharma et al. [11]. It resulted in the identification of
the genes for 309 surface proteins, among which 260 present
in at least 6 of the 8 examined strains were selected. Next, 147
proteins were selected for which it was possible to establish a
topology on the microorganism cell surface, and their origin
was determined. It appeared that many of these proteins are
factors of S. pyogenes virulence. After an analysis of 81 of the
147 genes, it was demonstrated that 82 % of them are present
in all the examined GAS isolates, while 73 of them (90.12 %)
occur in over 80 % of the isolates. As a result, 52 proteins
which may constitute the target of future vaccines were
presented. Genetic research is accelerating the creation of a
vaccine against GAS, since it considerably widens the list of
surface antigens which may be used. Additionally, they con-
firm the occurrence of particular proteins on numerous bacte-
rial strains, which may lead to successful worldwide applica-
tion of vaccinations. The research also established that sero-
type M1 is less invasive compared to serotype M49; however,
this requires confirmation via additional research [11].
GBS, S. agalactiae, has become an equally important
microorganism which is responsible for miscarriages, and
may also constitute a risk of premature birth and neonate
infection in the form of sepsis, pneumonia, or meningitis. In
the United States, GBS infection is diagnosed in about 5,000
neonates per year, and mortality caused by this microorgan-
ism is estimated at ca. 5 %.
Studies on S. agalactiae have provided information
concerning 27 main surface proteins of this species. They
include ornithine carbamoyltransferase (OCT) and protein
PGK, which react with antigens directed against them. These
proteins are the subject of scientific research aimed at their
application during the creation of vaccines against GBS. The
studies focused on GBS constitute a very important element
allowing the development of methods for the prevention of
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diseases caused by this microorganism, since no commercial
vaccine protecting against S. agalactiae infections has been
created so far [4].
The pathogenicity of S. mutans is primarily related to the
ability of adhesion to host cells. Biofilm formation is a
complex process engaging a number of proteins. Khan
et al. made a mutation of S. mutans, impairing the microor-
ganism’s ability to form biofilms. The modified strains were
characterized by poorer adhesion to surfaces covered with
saliva and by weakened biofilm formation. Confocal and
scanning microscope images confirmed that the biofilm in
these strains was thinner and looser compared to the biofilm
formed by nonimpaired strains. Forty-four proteins, the ex-
pression of which is higher in a situation of proper biofilm
formation, and 13 proteins of weakened expression were
identified using electrophoretic techniques [13]. The de-
scribed proteins relating to biofilm formation mainly include
glycosyltransferases (Gtf), which mediate biofilm matrix
synthesis, extracellular polysaccharides (EPS) [14, 15]. As
observed by Flemming and Wingender, there is no biofilm
without an EPS matrix [16]. The main components of EPS
are glucans synthesized from saccharose, which provide the
binding sites, and, thus, promote the accumulation of micro-
organisms and formation of cell clusters or microcolonies on
the tooth surface. S. mutans produces at least three kinds of
glycosyltransferases (Gtf): GtfB is related to insoluble glu-
can synthesis; GtfC synthesizes soluble and insoluble glu-
cans; GtfD mainly synthesizes soluble glucans. According to
Koo et al., GtfB and GtfC are essential for EPS matrix
formation, with GtfB being mainly responsible for S. mutans
aggregation [15] due to its high affinity to bacteria [17], GtfC
is adsorbed on the tooth surface, while GtfD acts as a starter
for GtfB [17]. Additionally, other surface proteins having an
affinity to glucan (glucan-binding proteins, Gbps) contribute
to biofilm growth by interactions of S. mutans with extracel-
lular glucan. There are at least four groups of glucan-binding
proteins, GbpsA, GbpsB, GbpsC, and GbpsD, differing in
terms of their affinity to glucan, structure, and immunolog-
ical properties. Duque et al. proved that GbpsB plays a role
in biofilm formation [14]. A microorganism adhering to the
enamel via glucan is the main saccharose-dependent way of
biofilm formation, but there is also a saccharose-independent
mechanism leading to biofilm formation [18]. Aggregation
under conditions independent of saccharose is based on in-
teractions between agglutinins present in saliva and P1
adhesins originating from S. mutans [18]. Agglutinins pres-
ent in saliva contribute to the process of S. mutans adhesion
and aggregation via interaction with antigen I/II, i.e., the
multifunctional adhesin P1 (also called AgB, adhesin SpaP,
or Pac1) embedded in bacteria cell walls and encoded by the
spaP gene [13, 18–20].
The family of Ag I/II proteins represented, inter alia, by
SpaP, SspA, or SspB proteins is identified not only on the
surface of S. mutans but also on other microorganisms, such
as Streptococcus pyogenes, Streptococcus agalactiae, or
Streptococcus suis [19]. The genetic sequence encoding Ag
I/II is composed of six separate regions. The most important
of them include region A rich in alanine and region P rich in
proline. Region V, which concentrates most of the various
sequences observed in particular strains, is localized between
them. Regions A and V encode adhesive epitopes occurring
on the surface of bacteria cells (so-called adhesintopes),
which are responsible for a microorganism’s affinity to saliva
glycoproteins [21]. The contribution of regions A, P, and V
in adhesion was confirmed in a study conducted using mu-
tant strains [19]. None of them demonstrated the ability to
adhere to solid surfaces covered with saliva membranes. The
expression and biological activity of protein P1 in S. mutans
also depends on numerous gene products, e.g., genes luxS,
ropA, and srtA (an encoding enzyme responsible for adhesin
P1 attaching to cell walls) [18, 22].
Protein SpaP, and other proteins from the Ag I/II family,
specifically interact with glycoprotein-340 (gp-340), which is
present in saliva. It is interesting that gp-340 dissolved in the
liquid phase of the saliva participates in bacterial cell aggre-
gation and, thus, eradicates them from the oral cavity. How-
ever, when gp-340 is absorbed on the surface of the teeth or
gums, it constitutes a receptor for surface bacterial adhesins
initiating adhesion processes [18, 19]. The AgI/II family of
proteins also participates in interactions between the microor-
ganisms, e.g., Streptococcus gordonii and Porphyromonas
gingivalis, as well as in the aggregation of cells lacking in
gp-340 [19]. The key role in interactions between S. mutans
and saliva agglutinins is played by the specific structure and
localization of protein P1, as has been proved thanks to an
application of this microorganism’s mutant strains (spaP and
srtA). It has additionally been demonstrated that the lack of the
expression of genes encoding the sortase A enzyme (SrtA)
results in not only an incorrect localization of adhesin P1, but
also of other surface proteins, which is significant in the
context of bacteria aggregation abilities [18].
The ability of S. mutans species bacteria to form biofilm is
significant from a clinical point of view not only in the
context of caries etiology, but also in cases of endocarditis
(IE) [23]. IE development is possible when the formation of a
very small clot rich in platelets and fibrinogen occurs as a
result of slight damage to the endocardium. When microor-
ganisms reach the blood at this time, they may use this
favorable medium for embedding and biofilm formation.
Such clots are formed most often at the edge of leaflets of
the mitral and tricuspid valves at the side of the atrium, and
on the aortic and pulmonary valves at the side of the ventri-
cles [24]. The survival of S. mutans in the bloodstream,
which it usually reaches after stomatological treatment, is
connected to the presence of a few pathogenicity factors on
the bacteria surface which have been described in various IE
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cases affected by this microorganism. Most importantly,
there are those factors responsible for an increase in protein
resistance to phagocytosis: a fibronectin-binding protein (so-
called autolysin A, AtlA) [25] and a serotypically specific
polysaccharide [26]. Next is antigen C, the expression of
which results in an increased aggregation of blood platelets
and, thus, increased coagulability [27].
The complexity of relationships between microorganisms
and hosts, as well as the differentiated expression of the
features determining microorganism pathogenicity, mean
that pathogenicity is an unpredictable phenomenon. This is
due to the fact that, even a complete understanding of both
the hosts and the microorganisms does not allow a determi-
nation of all possible interactions between them.
Due to an occurrence of some special properties of the
hosts and the microorganisms, different kinds of infectious
disease varieties are observed more often. The possibilities
offered by rapid worldwide travel contribute not only to
microorganism transfer in environments not inhabited by
them previously, but also enhance their virulence. We often
need decades of research on all factors affecting the patho-
genicity of microorganisms suspected of causing a given
disease in order to link some diseases with their causes.
Therefore, constant scientific interest in the interactions oc-
curring between microorganisms and hosts may contribute to
a deepening of knowledge concerning the pathogenicity of
an increasing number of microorganisms [28].
Pathogenicity of the Streptococcus genus
Bacteria of the Streptococcus genus include a large number
(>100 species) of microorganisms colonizing human and ani-
mal mucous membranes. They occur as physiological flora in
the oral cavity and intestines of humans and animals. In addi-
tion, they often inhabit the skin, throat, and upper respiratory
tract. However, numerous streptococci occur as opportunistic
pathogens, causing infections in the case of weak immunolog-
ical response of the host body they occupy. Pathogenic strep-
tococci may be divided into three groups: those commonly
causing infections in humans, and commensal and epizootic
species which cause disease symptoms under specified condi-
tions [4]. Typical pathogenic species include S. pneumoniae,
with S. pyogenes and S. agalactiae. According to the estima-
tions of the WHO, every year, pneumonia resulting mainly
from S. pneumoniae activity causes ca. 1.2 million deaths of
children younger than 5 years of age all over the world, which
constitutes 18 % of all deaths in this age group [5, 29]. S.
agalactiae (GBS) seems to be an equally dangerous microor-
ganism. It is the most often the cause of invasive neonate
infections, which occur in the form of sepsis, pneumonia
(80 % of cases), or, more rarely, meningitis (10 % of cases)
or pyarthrosis. In 4 % of cases, an infection ends with neonatal
death. It is estimated that ca. 10–30 % of pregnant women are
infected with GBS [30, 31]. An introduction of wide-scale
prevention caused the frequency of early GBS sepsis occur-
rence in neonates to drop to 3–4 cases per 10,000 live births in
2010 [32]. Human physiological streptococci which are able to
induce opportunistic infections include, e.g., S. mutans and S.
intermedius. Species responsible for opportunistic, epizootic
infections are S. canis (causing soft tissue infections, urinary
tract infections, bacteremia, bone infections, pneumonia), spe-
cies initially classified as S. bovis, especially including S.
equinus, S. bovis (causing endocarditis, bacteremia, meningi-
tis, sepsis) [4]. The consumption of infected milk resulted in
some cases of human infections (such as arthritis, endocarditis,
meningitis) with epizootic S. equi species, a zooepidemicus
subspecies [33] (see Fig. 1).
Streptococci inhabiting the oral cavity
According to the latest reports, Streptococcus species nor-
mally observed in the oral cavity may be pathogenic. An
example may be a case of healthy young men without risk
factors, in whom spleen abscess and brain abscess caused by
S. intermedius were diagnosed [39]. S. sanguis streptococci
of the Viridans group were the reason for breast implant
infection after wide-ranging stomatological treatment [40].
Over 60 cases in which S. salivariuswas an etiological factor
of meningitis as a result of iatrogenic infections have been
recorded [41]. Oral cavity streptococci such as S. sanguinis,
S. mitis, and S. gordonii were the reason for endocarditis
[42–44]. The latest (isolated from the synovial membrane
and synovial fluid of a 62-year-old man, and from the syno-
vial membrane of a 78-year-old woman in the second case)
was a reason for septic arthritis [45].
Despite the threats related to the above-mentioned bacte-
ria, caries is the most common disease in children. It occurs
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five times more often than the second disease in the range,
i.e., asthma [46]. In Poland, deciduous teeth caries concerns
35–50 % of the children between the second and third years
of life, and 56–60 % of the children between the ages of 3
and 4 years. At the age of 6–7 years, deciduous teeth caries is
observed in nearly 100 % of children in Poland. Permanent
teeth caries in Poland is noted in almost 90 % of children
aged 12 years [47]. In the United States, 50 % of children
aged 5–9 years have at least one cavity in the tooth or one
filling caused by dental caries focus. This number increases
up to 78 % by the age of 17 years [46]. Despite numerous
research on the etiology and development of the caries,
scientists are still not concordant towards some aspects of
this disease. Quite recently, S. mutans capable of biofilm
formation in the oral cavity has been considered as the main
factor causing caries [18, 48–51]. However, the fact that the
presence of S. mutans alone is not sufficient to cause disease
development has been the focus of increasing attention cur-
rently. The process of dental plaque formation and caries foci
development involves, except for S. mutans, a few hundred
other bacterial species, which, together, form the biofilm
structure [17, 46, 52–54]. Except for microbiological factors,
caries development also involves genetic, immunological,
and environmental factors, including diet [46, 53]. The spe-
cies having the three main phenotypic features allowing
them to survive in the oral cavity environment, i.e., ability
of adhesion (and, thus, biofilm formation), ability of acids
production, and ability of inhabiting an environment with
large pH fluctuations, osmolarity or oxygen availability fluc-
tuations, are considered as equally important species con-
tributing to environment acidification and caries foci forma-
tion. These mainly include: S. sobrinus, S. mitis, Actinomy-
ces spp., Lactobacillus spp., Bifidobacterium spp., and
Fusobacterium nucleatum [46, 52, 55]. While considering
the role of bacterial biofilm in the etiology of teeth and oral
cavity diseases, it should be also noted that its occurrence is
possible due to specific mutual interactions observed be-
tween microorganisms of the same or various species [46,
56]. Attention is focused on the examination of relations
observed during biofilm formation and its maturation, devel-
opment of resistance and wider spectrum of antibiotics,
analysis of the microorganism’s genome, and mechanisms
of specific bacterial protein activity [57–59]. Despite an idea
considering S. mutans as one of the main cariogenic factors
has been abandoned recently, this microorganism is still the
main target of scientific research.
S. mutans species may also cause endocarditis and bacter-
emia [23, 60] . S. mutanswas isolated from the heart valve in a
patient with endocarditis, which had already been described in
1977 [61]. Oral cavity streptococci are correlated with ob-
served endocarditis. This is an important issue from the point
of view of the growing resistance to penicillin among oral
cavity flora microorganisms (in the case of: S. mitis >24 %; S.
sanguis >19 %; S. mutans >14 %) [62]. S. mutans was also a
reason for recurring bacteremia in a woman with Sjögren’s
syndrome [63]. Besides endocarditis and bacteremia, S.
mutans may also cause sepsis [40]. It is speculated that S.
mutansmay be the cause of other constitutional diseases [64].
Also, a rare case of retroperitoneal abscess caused by S.
mutans has been described [65].
Sepsis
Streptococcus-caused sepsis is mainly related to severe S.
pneumoniae and S. pyogenes infections. The frequency of
invasive infections with S. pneumoniae in Poland is 0.78
cases per 100,000 people, while in children below 2 years of
age, 5.17 cases are noted; the mortality rate as a result of
these infections is 22.6 % [66]. In total, 364 cases of
pneumococci-caused diseases were noted in 2010, including
sepsis (172 cases), encephalitis and/or meningitis (180
cases), and other, unspecified diseases (63 cases) [67]. In
the same year, S. pneumoniae was the etiological factor of
meningitis in children up to the fourth year of life, and
encephalitis in 19.3 % of the patients [68]. In Europe, the
frequency of invasive S. pneumoniae infections range,
depending on the country, from 0.4 to 20 cases per 100,000
people [69]. In the United States, 6.3 cases per 100,000
people are noted in the population below 18 years of age
[70]. Such high incidence of the above-mentioned diseases
and mortality related to S. pneumoniae infections have
prompted scientists to an elaboration of vaccines aimed at
decreasing the number of incidents. It is known that the main
factor of microorganism pathogenicity is the polysaccharide
envelope [48], which was the basis of division for over 90
serotypes of the microorganism S. pneumoniae [7–9]. Poly-
saccharide antigens are used in pneumococcal vaccine and
are conjugated with proteins in order to enhance immuno-
logical response with respect to those which would have
been observed during natural infection with bacteria within
the polysaccharide envelope [10]. Conjugation of these sub-
stances allows an effective immunization of children below 2
years of age, who are a reservoir of numerous opportunistic
pathogenic bacteria as this stage of their lives [8]. Many
types of S. pneumoniae vaccines are distinguished; however,
7-, 10-, and 23-valent vaccines are used the most often. 7-
valent vaccine (protein conjugate vaccine, PCV7) contains
polysaccharide antigens which were found in seven sero-
types of the microorganisms responsible for 80–95 % of
invasive pneumococcal infections [49]. Its effectiveness is
confirmed by the data collected after the vaccine introduc-
tion in the United States—the number of cases of invasive
pneumococcal disease among children up to the 5th year of
age decreased by 94 % [71]. However, PCV7 does not
provide a homogenous effect for all vaccinal serotypes
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which it is aimed at. Comparing infections from the
period before and after 7-valent vaccine introduction in
the United States, the highest decrease in occurrence
(three-fold and more) was noted for serotypes 14, 9V,
and 23F. A two-fold decrease in the frequency of oc-
currence was observed for serotypes 18C and 6B, while
the lowest decrease was noted for serotype 19F. The
number of infections caused by nonvaccinal serotypes
was to be concurrently increasing.
Similar trends were observed in the case of strains
resistant to antibacterial substances. At the moment of
vaccines introduction, resistance among vaccinal sero-
types decreased about 1.5-fold, while the resistance of
nonvaccinal serotypes was doubled. An increase in the
number of noninvasive serotypes resistant to two or
more antimicrobial factors was also observed [7]. Po-
land introduced PCV7 to the vaccinations schedule in
2008, together with 22 other countries. In turn, 10-
valent vaccine obtained pre-qualification from the
WHO in 2010 [8]. It may be concluded from the
official data, that the number of people vaccinated
against pneumococci in Poland increased from
148,664 in 2009 to 155,258 in 2010. Despite this, in-
cidences of disease related to this pathogen infection
have not decreased [68].
Conjugated 13-valent vaccine (PCV13) of widened
spectrum of activity has been created as a response to
an increasing number of infections caused by
nonvaccinal serotypes [8]. It is composed, except for
antigens used in PCV7, of six additional polysaccharide
antigens characterizing further S. pneumoniae serotypes,
and they were combined with the same membrane pro-
tein, CRM197. These serotypes have been observed
most often in Africa, Asia, and Latin America, and are
consistent with serotypes causing 70 % of invasive
pneumococcal infections all over the world. It was also
demonstrated during the research that PCV13 may also
be used in children infected with the human immuno-
deficiency virus (HIV) virus, which, to a certain extent,
protected them against pneumococcal infections. The
13-valent vaccine was introduced in over 40 countries;
however, there is still a lack of documentation related to
this vaccine’s influence on the spread of infections
caused by S. pneumoniae around the world, confirming
a decrease in cases caused by S. pneumoniae serotypes
used in the vaccine [8].
Vaccine against S. pneumoniae targeted towards the
highest number of serotypes of this microorganism is
polysaccharide 23-valent vaccine (PPV23). It demon-
strated weak immunogenicity towards children; however.
it gained wide application in risk groups and among
older people [9]. This polysaccharide vaccine is not
conjugated with protein, and, therefore, should not be
administered in children less than years of age, and it
has been recommended since 2000 that PPV23 should
follow PCV7 vaccination [6].
Investigators suggest [9] that S. pneumoniae sero-
types such as 11A, 31, 10A, and 9N should be treated
in a prioritized manner in the creation of new vaccines
against this pathogen, since they are responsible for the
highest number of infections caused by nonvaccinal
serotypes.
The next significant reason for diseases occurrence and
mortality all over the world is invasive GAS infections. S.
pyogenes is responsible for ca. 700 million infections each
year, causing about 500,000 deaths [11]. In Europe, they are
noted with varying frequencies per 100,000 people: 3.12
cases in Great Britain [72]; 3.1 in France [73]; as much as
3.9 in Finland [74]. The mortality rate as a result of GAS
infection in these countries is 19, 14, and 9 %, respectively.
In the United States, the frequency of invasive GAS infec-
tions is similar: 3.5 cases per 100,000 people, with a mortal-
ity rate of 12.5 % [75] (see Fig. 2). GAS strains are concur-
rently responsible for ca. 18 million cases of rheumatic heart
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disease. resulting in a death of ca. 500,000 people each year.
A considerable relationship between GAS strains causing
pharyngitis in children and the strains related to invasive
disease in society was also observed. These data suggest that
schoolchildren may constitute a reservoir of infections for
society [78–80].
One of the most common S. pyogenes strains is
M1T1, which is responsible both for pharyngitis and
more severe states, such as necrotizing fasciitis or toxic
shock syndrome. This bacterium is equipped with fla-
gella referred to as antigen T. However, unlike in the
case of flagella noted in S. pneumoniae, their presence
in S. pyogenes causes a decrease in the invasiveness
and pathogenicity of the strain. Despite the similarity of
both kinds of flagella in general and their main genetic
structure, small differences in particular genes enable
functional diversity of encoded proteins. The flagella of
M1T1 strains increase the adhesive properties of bacte-
ria towards the endothelial tissue; however, they con-
currently constitute molecular standards for phagocytic
cells of the host, and, thus, are exposed by their in-
creased activity and faster elimination from an organism
[12] (see Table 1).
Despite the wide range of GAS-related research, no
licensed vaccine against this group of microorganisms
has been created so far [11]. This is affected by, e.g.,
large serotype differentiation of protein M, which was
the hope for an application in vaccines at the beginning
of the 21st century [4, 11]. A formulated 6-valent vac-
cine against GAS containing N-end parts of six sero-
types of protein M provided a desirable effect in tests
on animals—an increase in the antibodies index against
antigens contained within it. An increase in the antibod-
ies index was also demonstrated in the initial phase of
clinical studies, and, additionally, no cross-reactions
with human tissues were observed. The vaccine is sub-
ject to further tests; however, it is considered that its
disadvantage is protection against only 6 among 120
suggested serotypes of protein M [4]. The development
of genetic studies conducted on S. pyogenes may, in the
future, allow to elaborate on the methods which will
help identify antigens suitable for application in vac-
cines. Such research has been conducted in silico [11].
The result was an identification of genes for 309 surface
proteins, among which at least 260 were present in 6
among the 8 examined strains that were selected. Sub-
sequently, 147 proteins for which it was possible to
establish the topology on the microorganism cell surface
were selected, and their origin was established. It
appeared that many of these proteins constitute the
virulence factor of S. pyogenes. The analysis of 81
among 147 genes demonstrated that 82 % of them were
present in all the examined GAS isolates, while 73 ofTa
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them (90.12 %) were noted in over 80 % of isolates. As
a result, 52 proteins which may constitute a target for
future research have been presented. Genetic examina-
tion is an approach for the creation of vaccine against
GAS, since they considerably widen the list of surface
antigens which may be used for the process. Addition-
ally, they confirm an occurrence of particular proteins in
numerous bacterial strains, which may point towards the
success of vaccinations all over the world. It was also
established, as a result of the studies conducted, that
serotype M1 is less invasive than M49; however, this
needs to be verified by additional research [11] (see
Tables 1 and 2).
New species
Pathogenic species of the Streptococcus genus were
isolated and described as early as by the end of the
19th century [128, 129]. Subsequently, new species
have been discovered and described: Hardie and Whiley
in 1997 reported about ca. 40 species [130]; 10 years
later, ca. 50 species were known, and most of them
were pathogenic for humans [4]. Certainly, this number
is not definitive. An example is S. tigurinus, a species
discovered this year by Swiss researchers, and present
in the oral cavity as physiological flora; however, it
may be responsible for endocarditis and meningitis
[131]. Another example is a new subspecies of S.
gallolyticus identified in 2003, i.e., pasteurianus [132],
described for the first time as an etiological factor of
meningitis in an infant in 2009 (see Table 1) and in an
adult in 2010 (see Table 1). Another species is S.
urinalis—a case of bacteremia caused by this pathogen
[133] was described in a 60-year-old man with urethral
stricture history. S. australis, described initially as one
of the oral streptococci [134], also appeared to be an
etiological factor in the case of meningitis [135]. An
example of the species responsible for a range of hu-
man and animal infections (responsible for the sponta-
neous fermentation of dairy products in Africa) was S.
infantarius subsp. infantarius (Sii) belonging to S.
bovis/S. equinus, exhibiting 80 % similarity to the S.
thermophilus genome [136].
Summary
Infections with bacteria of the Streptococcus genus play
a significant role from a clinical point of view. Firstly,
the infections are of varying character, from local to
severe general infections (see Tables 1 and 2). Secondly,
the pathogenicity of the Streptococcus genus isTa
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connected not only to “classical” pathogens, but cases
of opportunistic infections are also described more of-
ten, e.g., species physiologically inhabiting the oral cav-
ity (S. intermedius, S. salivarius), where injuries or
surgical treatments may cause infections, and, worrying-
ly, cases of meningitis caused by S. intermedius without
previous risk factors have been reported [39]. Addition-
ally, streptococci are identified as one of the main
etiological factors of such severe diseases like pneumo-
nia, meningitis, or peritoneum inflammation, and also
diseases of a social character, like caries (see Fig. 1).
Caries appears to be a huge problem and, unfortunately,
there is a lack of suitable knowledge in the society
concerning risk factors (see Table 3), which results in
87 % of caries in children in Poland alone [148].
Comparing the results of CDL indices in 12-year-old
children for European countries, Poland is placed in the
next to last position (CDL=4.4), the best dentition state
is noted for children in Holland (CDL=0.9), while the
highest index was noted in Latvia (CDL=7.7) [47]. In
the United States, 50 % of children aged 5–9 years
have at least one cavity in their teeth [46].
Due to long-term research which has broadened the
scientific understanding of the virulence of specific
pathogens, scientists are able to create new vaccines,
which are oriented toward specific substances or anti-
gens occurring on the surface of given microorganisms.
This allows increased effectiveness in the fight against
infections caused by, e.g., S. pneumoniae. The Centers
for Disease Control and Prevention (CDC), WHO, and
National Institute of Hygiene, Poland (PZH) reports
reveal that the number of people vaccinated against
pneumococci has being increasing (in Poland, it grows
each year—from 2007 to 2011, the number of those
vaccinated increased by as much as 78,500) [5, 32,
149]. This points to increased awareness within society
and the application of pneumococcal infections prophy-
laxis. Despite this, morbidity-related infections caused
by this pathogen are not decreasing, and this is
connected to the new and pressing problem faced by
the medical world, i.e., the growing number of danger-
ous nonvaccine strains causing an increasing number of
infections in humans [7].
In the light of new taxonomic reports, differentiation
of the increasingly growing number of species and
subspecies, as well as the latest descriptions of cases
of particular species of Streptococcus infections, the
pathogenicity connected to the Streptococcus genus is
still not fully recognized and should be the subject of
further studies.
Table 3 Caries in children caused by Streptococcus spp.
Species Patient (n) age/sex Risk factors References
S. mutans n=133 Falling asleep with a bottle [137]
1–4 years Improper hygiene of the oral cavity
S. mutans n=3531 Passive smoking [138]
4–11 years
S. mutans Children <3 years Vertical and horizontal transmission [139]
Frequent meals consumption, pulpy
consistence of meals
Improper nutrition of pregnant mother
Early appearance of teeth weaken saliva
secretion, composition of saliva different
to in adults
S. mutans n=156 mother–infant pairs Caesarean section [140]
S. mutans n=109 Caesarean section [141]
3 years
S. mutans and Lactobacillus spp. Children <6 years Vertical and horizontal transmission [142]
Frequent consumption of sugars
S. mutans Children Transmission in early period of life [143]
Dietary factors
S. mutans and S. sobrinus n=54 S. mutans and S. sobrinus in mother [144]
2.5 years
S. mutans and S. sobrinus n=30 “Sticky desserts” [145]
Children Higher socioeconomic status (data from Sudan)
S. mutans 1–6 years S. mutans in mother [146]
Streptococci from Streptococcus mutans group Psychosocial, behavioral factors [147]
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